CLINICOPATHOLOGICAL EVALUATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR, EPIDERMAL GROWTH FACTOR RECEPTOR AND CARBOHYDRATE ANTIGEN 15-3 IN CANINE MAMMARY TUMOUR
Clinicopathological evaluation of tumor biomarkers in dogs
DOI:
https://doi.org/10.26873/SVR-1800-2026Keywords:
biomarkers, dogs, mammary tumor, ELISAAbstract
Mammary tumors are the most common neoplasms in unspayed female dogs. Biomarkers are biological molecules measured in blood or tissue that provide information for the presence of disease, treatment and prognosis. Tumor biomarkers can be used to determine cancer risk, early diagnosis, recurrence or progression. In this study, 125 tissue samples from 31 dogs with mammary tumor were included. It is aimed to evaluate the tissue estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor (EGFR) and carbohydrate antigen 15-3 (CA 15-3) in regard to different tumor types and clinicopathological parameters. Tumors included in the study; were evaluated in 3 groups as malignant epithelial tumors group (MET, n=66), hyperplasia&dysplasia (H&D, n=43) group and benign mammary tumor (BMT, n=16) group. The highest ER and PR levels were determined in group BMT (P<0.05). Also, CA 15-3 level in group MET was significantly higher than in group H&D (P=0.01). However, the evaluated biomarkers in group MET were not different with regard to clinicopathological parameters such as histological subtypes and grading, tumor size, and invasion (P>0.05). In this study, ER was moderately and positive correlated with PR (r=0.383, P<0.001) while it was low and positive correlated with EGFR (r=0.223, P<0.05). Also, CA 15-3 was moderately and positive correlated with EGFR (r=0.376, P<0.001) while it was low and positive correlated with PR (r=0.216, P<0.05). This study stated that ELISA is capable enough to detect the ER, PR, EGFR and CA 15-3 in canine mammary tumor tissue. In conclusion, ER and PR can distinguish benign tumor from malignant tumor and H&D, while CA 15-3 can distinguish malignant tumor from H&D.
References
Brоnden LB, Flagstad А, Kristensen AT. Veterinary cancer registry in com-panion animal cancer; a review. Vet Comp Oncol 2007; 5(3): 133–44.
Šoštarić-Zuckermann IC, Severin K, Hohšteter M, et al. Incidence and types of canine tumours in Croatia. Vet Arh 2013; 83(1): 31–45.
Sarver AL, Makielski KM, DePauw TA, Schulte AJ, Modiano JF. Increased risk of cancer in dogs and humans: A consequence of recent extension of lifespan beyond evolutionarily determined limitations? Aging Cancer 2022; 3(1): 3–19.
Zuchi TLVL, Lopatini CL, Faria JLM. Veterinary approaches to canine mammary tumors and knowledge of the consensus statement in Brazil. Braz J Vet Pathol 2021; 14: 24 – 28.
Nikodinovska T, Gombač M, Dolenšek T, Tekavec K, Šturm S, Cvetko M, Pavlin K, Fras DM, Švara T. Incidence and types of canine tumours in Slovenia (2000-2020): A Retrospective study. Slovenian Veterinary Research 2025; 62(27): 27-39.
Henry JC. Biomarkers in veterinary cancer screening: applications, limita-tions and expectations. Vet J 2010; 185: 10–14.
Mobasheri A, Cassidy J. Biomarkers in veterinary medicine: towards tar-geted, individualised therapies for companion animals. Vet J 2010; 185: 1–3.
Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. Br Med J 2009; 339: 852-8.
Kim NH, Lim KY, Im KS. Evaluation of clinicopathological characteristics and oestrogen receptor gene expression in oestrogen receptor-negative, progesterone receptor- positive canine mammary carcinomas. J Comp Pathol 2014; 151: 42–50.
Queiroga FL, Perez-Alenza D, Gonzalez-Gil A, Silvan G, Peňa L, Illera JC. Serum and Tissue Steroid Hormone Levels in Canine Mammary Tumours: Clinical and Prognostic Implications. Reprod Dom Anim 2015; 50: 858–865.
Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 2014; 5: 283-298.
Mc Cormack O, Harrison M, Kerin MJ, McCann A. Role of the progester-one receptor (PR) and the PR isoforms in breast cancer. Crit Rev Oncog 2007; 13: 283-301.
Kim JH, Im KS, Kim NH. Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immuno-histochemical study. Vet J 2011; 189: 318–22.
Carvalho MI, Guimarães MJ, Pires I, et al. EGFR and microvessel density in canine malignant mammary tumours. Res Vet Sci 2013; 95: 1094–1099.
Manuali E, De Giuseppe A, Feliziani F, et al. CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. BMC Vet Res 2012; 8: 86-98.
Hollinghsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Canc 2004; 4: 45–60.
Martin A, Corte MD, Alvarez AM, Rodriguez JC, Andicoechea A, Bongera M, Junquera S, Pidal D, Allende T, Muñiz JL, Vizoso F. Prognostic value of pre-operative CA 15.3 levels in breast cancer. Antican. Res 2006; 26(5B): 3965–3971.
Agrawal AK, Jelen M, Rudnicki J, Grzebieniak Z, Zyśko D, Kielan W, Słolina J, Marek G. The importance of preoperative elevated serum levels of CEA and CA 15–3 in patients with breast cancer in predicting its histological type. Folia Histochem Cytobiol 2010; 48(1): 26–29.
Illera JC, Perez-Alenza MD, Nieto A, et al. Steroids and receptors in canine mammary cancer. Steroids 2006; 71: 541-48.
Queiroga FL, Perez-Alenza MD, González-Gil A, Silván G, Peña L, Illera JC. Quantification of epidermal growth factor receptor (EGFR) in canine mam-mary tumours by ELISA assay: clinical and prognostic implications. Vet Comp Oncol 2017; 15: 383–390.
Owen LN. TNM Classification of tumors in Domestic Animals, World Health Organization, Geneva, Switzerland, 1980.
Thuroczy J, Reisvaag GJK, Perge E, Tibold A, Szilagyi J, Balogh L. Immuno-histochemical detection of Progesterone and Cellular Proliferation in Canine Mammary Tumors. J Comp Pathol 2007; 137: 122-129.
Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A. Compar-ison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci 2005; 79: 225-232.
De Las Mulas JM, Van Niel M, Millán Y, Blankenstein MA, Van Mil F, Mis-dorp W. Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemi-cal assay. Domest Anim Endocrinol 2000; 18: 111-125.
Hatsumi T, Yamamuro Y. Downregulation of estrogen receptor gene expression by exogenous 17beta-estradiol in the mammary glands of lac-tating mice. Exp Biol Med 2006; 231: 311-316.
Donnay I, Devleeschouwer N, Wouters-Ballman P, Leclercq G, Verstegen J. Relationship between receptors for epidermal growth factor and steroid hormones in normal, dysplastic and neoplastic canine mammary tissues. Res Vet Sci 1996; 60: 251–254.
Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003; 7: 309–317.
Gama A, Gärtner F, Alves A, Schmitt F. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in canine mammary tissues. Res Vet Sci 2009; 87: 432–437.
Jain M, Ingole SD, Deshmukh RS, et al. CEA, CA 15-3, and miRNA expres-sion as potential biomarkers in canine mammary tumors. Chromosome Res 2021; 29: 175–188.
Ramadan ES, Salem NY, Emam IA, AbdElKader NA, Farghali HA, Khattab MS. MicroRNA 21 expression, serum tumor markers, and immunohisto-chemistry in canine mammary tumors. Veter Res Commun 2021; 46: 377-388.
Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. Plos One 2015; 10: 1–11.
Hashim ZM. The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status. Int J Immunopathol Pharmacol 2014; 27: 45–51.
Millanta F, Calandrella M, Vannozzi I, Poli A. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prog-nostic significance. Vet Rec 2006; 158: 821-824.
Günay Uçmak Z, Timirci Kahraman Ö, İnal Gültekin G, Değirmencioğlu S, Yaylım İ, Güvenç K. Determining the expression levels of circulating tumour cell markers in canine mammary tumours. Acta Vet Brno 2021; 90: 191–200.
Canadas A, França M, Pereira C, et al. Canine mammary tumors: compari-son of classification and grading methods in a survival study. Vet Pathol 2019; 56: 208–219.
Kaszak I, Ruszczak A, Kanafa S, Kacprzak K, Król M, Jurka P. Current bi-omarkers of canine mammary tumors. Acta Vet Scand 2018; 60: 66.
De Las Mulas JM, Millán Y, Dios R. A Prospective Analysis of Immuno-histochemically Determined Estrogen Receptor and Progesterone Receptor Expression and Host and Tumor Factors as Predictors of Disease-free Period in Mammary Tumors of the Dog. Vet Pathol 2005; 42: 200–212.
Vogl G, Bartel H, Dietze O, Hauser-Kronberger C. HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer. Appl Immunohistochem Mol Morphol 2006; 14: 138–145.
Kallel I, Khabir A, Boujelbene N, et al. EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tuni-sia. J Recept Signal Transduct Res 2012; 32: 142–149.
Mainenti M, Rasotto R, Carnier P, Zappulli V. Oestrogen and progesterone receptor expression in subtypes of canine mammary tumours in intact and ovariectomised dogs. Vet J 2014; 202: 62–68.
Campos LC, Lavalle GE, Estrela-Lima A, et al. CA15.3, CEA, and LDH in Dogs with Malignant Mammary Tumors. J Vet Intern Med 2012; 26: 1383–1388.
Günay Uçmak Z, Güvenç K. Malign Meme Tümörlü Dişi Köpeklerde Klinik ve Bazı Hematolojik Parametreler Arasındaki İlişkinin Değerlendirilmesi. Türkiye Klinikleri J Vet Sci 2019; 10: 45-52
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Çağla Nur Küçükbekir, Çağatay Tek, Zeynep Günay Uçmak*, Atila Ates
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
